15 results about "Premalignant Cell" patented technology

The invention discloses a dynamic identification method for unusual cells before young tumors based on multi-omics data, and relates to the technical field of cell unusual identification. A dynamic correlation intensity matrix and a cumulative effect contribution matrix are constructed, a differentiation screening strategy is implemented according to individual response characteristics, and the unusual cells before young tumors are identified. And the abnormal dynamic high-fidelity identification of the young tumor pre-cells is realized. And aiming at individuals of different response types, an instant path, a long-term path or a double-path fusion strategy is respectively adopted, key behavior data is accurately screened, and the input quality is improved. According to the method, redundant interference is effectively eliminated, the simulation capability of the model on key processes such as immunosuppression and DNA damage accumulation is enhanced, the biological rationality and prediction precision of a cell state evolution sequence are remarkably improved, and the problems of model response lag, low calculation efficiency and output distortion caused by data noise in the prior art are solved; and a reliable technical support is provided for early warning and individualized intervention of precancerous lesions.

The invention discloses a drug perturbation diffusion prediction method fused with cell description, and relates to the technical field of drug perturbation prediction.The method comprises the steps that firstly, a cell perturbation transcriptome database is preprocessed, and a cell-drug combination containing drug characteristics, cell line gene expression and cell line description characteristics is obtained to serve as training data; and then constructing a drug disturbance prediction diffusion model based on cell description, training the drug disturbance prediction diffusion model by using the training data, and finally inputting Gaussian white noise, cell line gene expression before disturbance, drug characteristics and cell line description characteristics into the trained model to predict cell line gene expression after drug disturbance. According to the method, cell line description characteristics are introduced, so that the perception capability of the model on intercellular biological differences is enhanced, and the generalization performance of cross-drug and cross-cell lines is improved.

The subject matter of this specification can be implemented in, among other things, methods, systems, computer-readable storage medium. A method can include receiving cell growth data with a current cell culture of a cell growth system. The cell growth data includes growth input parameter values indicative of a growth rate of the current cell culture. The method can further include identifying, using a first machine learning model, a prescriptive action to alter a yield of a target product of the current cell culture based on the cell growth data. The prescriptive action modifies a metabolism rate of the current cell culture. The method further includes performing at least one of displaying the identified prescriptive on a graphical user interface (GUI) and / or causing the cell growth system to perform the identified prescriptive action.

The present disclosure is directed to method of generating human glomeruli endothelial cells (HGECs) from human endothelial cells (ECs), comprising expressing in human ECs an exogenous nucleic acid encoding a T-box transcription factor 3 (Tbx3), alone or in combination with one or more of PR domain zinc finger protein 1 (Prdm1), GATA Binding Protein 5 (Gata5) and Pre-B-Cell Leukemia Transcription Factor 1 (Pbx1). Disclosed also are HGECs produced by the methods of the instant disclosure, as well as methods for using the same.

The application discloses a kind of young tumor pre-cell abnormal dynamic identification method based on multi-omics data, it is related to cell abnormality identification technical field, the application is by constructing dynamic correlation strength matrix and cumulative effect contribution matrix, according to individual response characteristics Implementation of differentiating screening strategy, realize the high fidelity identification of young tumor pre-cell abnormal dynamics.For different response type individuals, respectively using instant path, long-term path or double-path fusion strategy, accurately screening key behavior data, improve input quality.The method effectively eliminates redundant interference, enhances the model's ability to simulate key processes such as immune suppression and DNA damage accumulation, significantly improves the biological rationality and prediction accuracy of cell state evolution sequence, solves the model response lag, low computational efficiency and output distortion problems caused by data noise in the prior art, and provides reliable technical support for early warning and individualized intervention of pre-tumor lesions.

The invention discloses a high-bionic in-vivo immune microenvironment in-vitro skin model and application, and belongs to the technical field of biological medicine. The preparation method of the in-vitro skin model of the high-bionic in-vivo immune microenvironment comprises the following steps: firstly, adding a culture medium into the lower layer of a six-pore plate, then adding a mouse bone marrow cell suspension, then putting the six-pore plate into a Transwell chamber, flatly laying separated mouse skin on an absorptive gelatin sponge, putting the absorptive gelatin sponge into the Transwell chamber, adding the culture medium into the Transwell chamber, and then putting the mouse skin into the transwell chamber to obtain the in-vitro skin model of the high-bionic in-vivo immune microenvironment. Placing the six-hole plate in a cell incubator for culturing to obtain the in-vitro skin model. According to the in-vitro skin-bone marrow cell co-culture system, an immune environment is provided for the in-vitro skin by introducing bone marrow cells, so that the culture environment of the in-vitro skin is more complete, the difficulties that cell components are simple and the immune environment is deficient at present can be solved, and the in-vitro skin-bone marrow cell co-culture system is more in line with the 3R principle and is high in bionic property and low in cost.

The invention belongs to the technical field of nano medicine, and particularly discloses a method for obtaining exosomes with different cell biological functions, which comprises the following steps: preparing hybrid cells HCs integrating different cell functions by a cell fusion method, and further collecting exosomes H / Exos derived from the hybrid cells. The invention also discloses the exosome and application of the exosome in preparation of drugs. Different hybrid cells have multiple functions of cells before fusion, and exosomes secreted by the hybrid cells inherit the functions of the hybrid cells. The hybrid cells can continuously secrete exosomes with the characteristics of the two parent cells in the proliferation process. The defect that the end-to-end differentiated cells cannot be proliferated is overcome, so that large-scale preparation of the natural multifunctional exosome can be realized, and a new method is provided for customized exosome preparation for disease treatment.

Methods for treating leukemia are disclosed based on detecting specific cell states and transcriptional programs within leukemic cells. This disclosure presents a novel therapeutic method for treating acute lymphoblastic leukemia (ALL), including BCR-ABL positive and BCR-ABL1-like ALL subtypes. The method involves detecting specific cell states and transcriptional programs in patient samples and administering targeted therapies based on these characteristics. For a pre-B cell-like state or pre-BCR signaling program, a combination of tyrosine kinase inhibitor (TKI) and SYK inhibitor is used. Conversely, a progenitor-like state or stress-autophagy program is treated with a TKI and a p38 MAPK inhibitor. This approach aims to improve treatment efficacy by tailoring therapy to the leukemia's unique molecular and cellular features, particularly in relapsed cases or when minimal residual disease is present.

Provided are activatable proprotein homodimers comprising two separate but identical polypeptide chains, each chain comprising a fragment antigen-binding (Fab) region that specifically binds to human PD-1 or human PD-L1 or human B7H3, a hinge / Fc domain, a linker, an IL-2 protein, a protease cleavable linker, and an IL-2Rα protein. Also provided are related pharmaceutical compositions and methods of use thereof.

Provided herein are populations of IL2 dependent cells that express high affinity CD16 but do not express IL-2. The cells maintain stable expression of the Fc receptor CD16 while maintaining cytotoxicity. In some embodiments, the expression level of CD16 when the cell is activated is reduced by no more than 20% compared to the expression level of CD16 on the cell prior to activation. Also provided are compositions and kits comprising the cells, as well as methods of making and using IL2 dependent cells.

Nanostraws and to methods of utilizing them in order to deliver biologically relevant molecules such as DNA, RNA, proteins etc., into non-adherent cells such as immune cells, embryos, plant cells, bac- teria, yeast etc. The methods described herein are repeatedly capable of delivering biologically relevant cargo into non-adherent cells, with high cell viability, dosage control, unaffected proliferation or cellular devel- opment, and with high efficiency. Among other uses, these new delivery methods will allow to scale pre-clinical cell reprogramming techniques to clinical applications.

An apparatus and method for controllably moving a containment vessel for mammalian gestation, including to provide continuous intermittent motion and culture of an embryo in the containment vessel. The method includes determining compatibility or biocompatibility of a material or substance for gestational development of an embryo. The apparatus includes a motion system having one or more fasteners configured to attach to the containment vessel, a platform configured to support the motion system and allow the containment vessel to move with respect at least one axis while being imaged by an image pickup device, and a drive system having a controller configured to adjust movement of the containment vessel with respect to the at least one axis, including at least one of an inversion frequency, a direction of rotation, a velocity, a rate of change in the inversion frequency, a rate of change in the direction of rotation, and a rate of change in the velocity of the containment vessel, for mammalian gestation.

The invention provides an ATG13 gene and application of the ATG13 gene in improvement of exogenous recombinant protein expression, and belongs to the technical field of gene engineering. The nucleotide sequence of the ATG13 gene provided by the invention is as follows: (1) a nucleotide sequence as shown in SEQ ID NO.2; or (2) a nucleotide sequence which is obtained by substituting and / or deleting and / or adding one or more nucleotides to the nucleotide sequence as shown in SEQ ID NO.2 and expresses the same functional protein. Furthermore, through overexpression of the ATG13 gene in the CHO cell, the expression quantity of the exogenous recombinant protein can be remarkably improved, the problem that the expression level of an existing CHO cell expression system is low is effectively solved, and a direction is provided for construction of the CHO cell and production of the recombinant protein.

Described herein are methods of using fusion proteins consisting of elements such as one or more proteins / polypeptides capable of translocation into the endoplasmic reticulum (ER) and fragments or variants of interleukin 18 (IL-18) or IL-18. Proteins / polypeptides capable of translocation into the ER include, but are not limited to, immunoglobulins such as Fc regions, VHH antibodies and scFvs, and globular proteins such as serum albumin. IL-18 can be a precursor IL-18 similar to a native procytokine, wherein IL-18 is fused to the C-terminus of its propeptide or propeptide variant. These fusion proteins are useful in methods of treating cancer or fibrosis by activating IL-18 receptor complex (RC) signaling on a cell, releasing or exposing mature IL-18 in or adjacent to a tumor, and / or increasing memory CD8-T cell proliferation.

The invention relates to the technical field of gene engineering. The invention provides an application of an SFN gene in improvement of CHO cell recombinant protein expression stability. A nucleotide sequence of the SFN gene is shown as SEQ ID NO.1. The invention further provides an application of the SFN gene in improvement of CHO cell recombinant protein expression stability. The SFN overexpression vector is constructed and transfected to the recombinant CHO cell, the recombinant CHO cell overexpressing the SFN is obtained through screening, cell passage is carried out, in the long-term culture process of the recombinant CHO cell overexpressing the SFN, the expression attenuation of the recombinant antibody can be obviously slowed down, the expression stability of the recombinant antibody is improved, and the recombinant CHO cell overexpressing the SFN is obtained. The problem of recombinant protein expression attenuation caused by cell passage at present is effectively solved.